CYTK - Cytokinetics, Incorporated
| Previous Close | 9.94 |
| Open | 9.84 |
| Bid | 9.54 x 900 |
| Ask | 10.25 x 4000 |
| Day's Range | 9.53 - 10.04 |
| 52 Week Range | 5.75 - 11.33 |
| Volume | 278,961 |
| Avg. Volume | 572,788 |
| Market Cap | 550.661M |
| Beta (3Y Monthly) | 1.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.93 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
- Simply Wall St.•3 days ago
Could The Cytokinetics, Incorporated (NASDAQ:CYTK) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Cytokinetics, Incorporated (NASDAQ:CYTK) can tell us which group is most powerful...
- GlobeNewswire•4 days ago
Cytokinetics to Present at the JMP Securities Life Sciences Conference
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 9:00 AM EST at the St. Regis Hotel in New York. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event.
- Thomson Reuters StreetEvents•4 days ago
Edited Transcript of CYTK earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Cytokinetics Inc Earnings Call
- GlobeNewswire•17 days ago
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
Cytokinetics, Incorporated (CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. “The ALS Association and The ALS Association Golden West Chapter have been exceptional partners over the many years we’ve worked together in supporting patients, caregivers, and advocates of our ALS community,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.
Motley Fool•last monthCytokinetics Inc (CYTK) Q1 2019 Earnings Call Transcript
CYTK earnings call for the period ending March 31, 2019.
- Zacks•last month
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.89% and 36.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Cytokinetics: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 54 cents per share. The biopharmaceutical company posted revenue of $8.5 million in the period. Cytokinetics shares have increased ...
- GlobeNewswire•last month
Cytokinetics Reports First Quarter 2019 Financial Results
GALACTIC-HF Continues Following Interim Analysis for Futility; METEORIC-HF Opened to Enrollment Phase 1 Data for CK-274 Expected in Q3 2019; Planning Underway for Potential.
- GlobeNewswire•last month
Cytokinetics to Hold Annual Meeting of Stockholders
Cytokinetics, Incorporated (CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 15, 2019 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.
- American City Business Journals•last month
Investors scrutinize Peninsula biotech company as Lou Gehrig's disease drug falters
The South San Francisco company says its mid-stage study was one of the best for people with ALS; investors initially were skeptical.
- MarketWatch•last month
Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints
Shares of biotech Cytokinetics Inc. plunged 19% in premarket trade Monday after the company announced that a Phase 2 study of its amyotrophic lateral sclerosis drug did not show a meaningful difference in respiratory function, muscle strength or daily living measures compared with placebo. After 12 weeks on the drug, called reldesemtiv, patients did not show a statistically-significant difference in symptoms at three different dosage points when compared with patients on a placebo, though a post-hoc analysis grouping all treatment groups together showed improvement in daily living compared with placebo. Shares of Cytokinetics have gained 40% in the year to date, while the S&P 500 has gained 17.5%.
- GlobeNewswire•last month
Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting
Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) announced that results of FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS) were presented today by Jeremy Shefner, M.D., Ph.D., Lead Investigator of FORTITUDE-ALS, Professor and Chair of Neurology at Barrow Neurological Institute, and Professor and Executive Chair of Neurology at the University of Arizona, Phoenix, at a podium presentation at the American Academy of Neurology Annual Meeting in Philadelphia. FORTITUDE-ALS did not achieve statistical significance for a pre-specified dose-response relationship in its primary endpoint of change from baseline in slow vital capacity (SVC) after 12 weeks of dosing (p=0.11).
- Zacks•last month
Will Cytokinetics (CYTK) Report Negative Earnings Next Week? What You Should Know
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
Cytokinetics to Announce First Quarter Results on May 9, 2019
Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report first quarter results on May 9, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.
- Simply Wall St.•2 months ago
What Are Analysts Expecting From Cytokinetics, Incorporated (NASDAQ:CYTK) In The Next Couple Of Years?
Cytokinetics, Incorporated's (NASDAQ:CYTK) released its most recent earnings update in December 2018, which signalled company earnings became less negative compared to the previous year's level as a...
- Zacks•2 months ago
Will Cytokinetics (CYTK) Report Negative Q1 Earnings? What You Should Know
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
Cytokinetics to Present at April Investor Conferences
The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
- GlobeNewswire•2 months ago
New Research Coverage Highlights International Paper, Square, Sealed Air, Calix, e.l.f. Beauty, and Cytokinetics — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•3 months ago
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
Key highlights of the past week are multiple study failures and other pipeline updates.
- Benzinga•3 months ago
The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 20) AstraZeneca plc (NYSE: AZN ) BioDelivery Sciences ...
- Motley Fool•3 months ago
Here's Why Cytokinetics Stock Jumped Today
The clinical-stage biotech's long-running partnership with Amgen took another big step forward.
- GlobeNewswire•3 months ago
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct. The futility analysis was triggered once a pre-specified number of cardiovascular deaths had occurred in GALACTIC-HF as stipulated by the trial’s protocol.
- PR Newswire•3 months ago
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
THOUSAND OAKS, Calif., and SOUTH SAN FRANCISCO, Calif., and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The futility analysis was triggered once a pre-specified number of cardiovascular deaths had occurred in GALACTIC-HF as stipulated by the trial's protocol.
- GlobeNewswire•3 months ago
Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19
Cytokinetics, Incorporated (CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, were presented by John Teerlink, M.D., Professor of Clinical Medicine, University of California San Francisco and Director of Heart Failure, San Francisco Veterans Affairs Medical Center, in a Moderated Poster Session at the American College of Cardiology’s 68th Annual Scientific Session (ACC.19) in New Orleans.
- GlobeNewswire•3 months ago
Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19
SOUTH SAN FRANCISCO, Calif., March 11, 2019 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin.
